Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial

Keyphrases

• Dravet Syndrome 100%
• Cannabidiol 100%
• Extension Trial 100%
• Open-label Extension 100%
• Adverse Events 60%
• Seizure Frequency 40%
• Caregivers 20%
• Clinically Significant 20%
• Randomized Trial 20%
• Seizure 20%
• Modal 20%
• Treatment-resistant 20%
• Patient-reported Outcomes 20%
• Patient Caregivers 20%
• Placebo-controlled Trial 20%
• Antiepileptic Drugs 20%
• Safety Efficacy 20%
• Randomized Placebo-controlled Trial 20%
• Diarrhea 20%
• Safety Profile 20%
• Oral Solution 20%
• Interim Analysis 20%
• Treatment Duration 20%
• Convulsive Seizures 20%
• Valproic Acid 20%
• Upper Normal Limit 20%
• Day Range 20%
• Somnolence 20%
• Liver Transaminases 20%
• Acceptable Safety 20%
• Total Seizures 20%
• Safety Patient 20%
• Transaminase Elevations 20%
• Patient Global Impression of Change 20%
• Pyrexia 20%
• Decreased Appetite 20%
• Pharmaceutical Formulations 20%

Medicine and Dentistry

• Severe Myoclonic Epilepsy of Infancy 100%
• Epileptic Seizure 100%
• Cannabidiol 100%
• Adverse Event 60%
• Placebo 40%
• Treatment Duration 20%
• Patient-Reported Outcome 20%
• Diarrhea 20%
• Somnolence 20%
• Transaminase 20%
• Interim Analysis 20%
• Decreased Appetite 20%
• Pharmaceutical Formulation 20%
• Sodium Valproate 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Cannabidiol 100%
• Severe Myoclonic Epilepsy in Infancy 100%
• Adverse Event 60%
• Placebo 40%
• Sodium Valproate 20%
• Diarrhea 20%
• Aminotransferase 20%
• Decreased Appetite 20%
• Somnolence 20%